Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

However, with scarce training, few region-specific guidelines, and symptoms that often mimic common eye problems, many ...

Here are four patient and professional organizations that provide information and support for people who are living with ...

Danish archaeologists unearthed dozens of medieval graves, shedding light on how disease and hardship shaped life in early ...

The CALM-CAH Phase 3 study is a randomized, placebo-controlled trial evaluating atumelnant in adults with classic CAH, designed to assess reductions in excess androgens, improvements in glucocorticoid ...

Scientists remain divided over whether the human Y chromosome will eventually vanish. But clinicians say the real concern ...

Immunovant ( ($IMVT) ) has issued an announcement. On December 10, 2025, Immunovant announced the pricing of an underwritten offering of its ...

Watts challenged the decision in the Personal Injury Commission and represented himself during the proceedings. EML’s case ...

Williams] does not have frontotemporal dementia, so that should be game, set, match,” famed attorney Joe Tacopina said in an ...

Archaeologists in Norway have excavated a Viking Age grave of an individual bedecked in costume and jewelry, as reported by ...

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...